0001372514-24-000096.txt : 20240703
0001372514-24-000096.hdr.sgml : 20240703
20240703151641
ACCESSION NUMBER: 0001372514-24-000096
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240701
FILED AS OF DATE: 20240703
DATE AS OF CHANGE: 20240703
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Tosca Melissa
CENTRAL INDEX KEY: 0001947184
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36672
FILM NUMBER: 241099811
MAIL ADDRESS:
STREET 1: C/O KIORA PHARMACEUTICALS, INC.
STREET 2: 1371 EAST 2100 SOUTH, SUITE 200
CITY: SALT LAKE CITY
STATE: UT
ZIP: 84105
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: KIORA PHARMACEUTICALS INC
CENTRAL INDEX KEY: 0001372514
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 332 ENCINITAS BOULEVARD
STREET 2: SUITE 102
CITY: ENCINITAS
STATE: CA
ZIP: 92024
BUSINESS PHONE: 781-788-8869
MAIL ADDRESS:
STREET 1: 332 ENCINITAS BOULEVARD
STREET 2: SUITE 102
CITY: ENCINITAS
STATE: CA
ZIP: 92024
FORMER COMPANY:
FORMER CONFORMED NAME: EYEGATE PHARMACEUTICALS INC
DATE OF NAME CHANGE: 20060811
4
1
wk-form4_1720034195.xml
FORM 4
X0508
4
2024-07-01
0
0001372514
KIORA PHARMACEUTICALS INC
KPRX
0001947184
Tosca Melissa
C/O KIORA PHARMACEUTICALS, INC.
332 ENCINITAS BLVD., SUITE 102
ENCINITAS
CA
92024
0
1
0
0
CFO
0
Common Stock
2024-07-01
4
A
0
7620
0
A
11599
D
Stock Option (right to buy)
4.35
2024-07-01
4
A
0
15239
0
A
2025-07-01
2034-07-01
Common Stock
15239
15239
D
Grant of restricted stock from the Issuer pursuant to the Issuer's 2024 Equity Incentive Plan (the "Plan"). The restrictions will vest as to one-third (1/3) of the shares on each of July 1, 2025, July 1, 2026 and July 1, 2027, subject to the reporting person's continuous service through each such vesting date.
The reporting person received an option to purchase Common Stock from the Issuer pursuant to the Plan. The option will become exercisable as to one-third (1/3) of the shares underlying the Option on July 1, 2025, and the remaining balance vests monthly on the first day of each calendar month thereafter for a period of two years, subject to the reporting person's continuous service through each such vesting date.
/s/ Melissa Tosca, Attorney-in-Fact
2024-07-03